Medium-chain length fatty acids, salts and triglycerides in combination with gemcitabine for treatment of pancreatic cancer
AssigneePrometic Biosciences Inc.
InventorsLyne Gagnon, Lilianne Geerts, Christopher Penney
Life of this patent
Estimating the term…
Abstract
The present invention relates to the use of medium-chain length fatty acids of formula I, triglycerides of formula 2 (wherein n=6-10), salts thereof, or mixtures thereof, in combination with gemcitabine and optionally erlotinib in the treatment of pancreatic cancer in human patients. Exemplary medium-chain length fatty acid/triglyceride compounds include capric acid, sodium caprate, tricaprin, lauric acid, sodium laurate, and trilaurin.
Claims14
A method of treating pancreatic cancer, said method comprising administering to a human patient in need thereof a pharmacologically effective amount of a compound represented by Formula I or Formula II:
- wherein n is 8 and X is hydrogen, a metallic monocationic counterion or a dicationic counterion;
- in combination with (i) gemcitabine or (ii) gemcitabine and erlotinib;
- wherein said gemcitabine is administered at a subtherapeutic dosage.
A method for treating pancreatic cancer in a human patient in need thereof, the method comprising administering to said patient:
- (a) a compound represented by Formula I or Formula II:
- wherein n is 8 and X is hydrogen, a metallic monocationic counterion or a dicationic counterion;
- and
- (b) at least one (i) gemcitabine or (ii) gemcitabine and erlotinib;
- wherein (a) and (b) are administered according to a dosage regimen providing a synergistic antitumor activity.
Dependencies are inferred from the claim text.